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Abstract
Rhodopsin, the light sensitive receptor responsible for blue-green vision, serves as a prototypical G
protein-coupled receptor (GPCR). Upon light absorption, it undergoes a series of conformational
changes that lead to the active form, metarhodopsin II (META II), initiating a signaling cascade
through binding to the G protein transducin (Gt). Here, we first develop a structural model of META
II by applying experimental distance restraints to the structure of lumi-rhodopsin (LUMI), an earlier
intermediate. The restraints are imposed by using a combination of biased molecular dynamics
simulations and perturbations to an elastic network model. We characterize the motions of the
transmembrane helices in the LUMI-to-META II transition, and the rearrangement of interhelical
hydrogen bonds. We then simulate rhodopsin activation in a dynamic model to study the path leading
from LUMI to our META II model for wild-type rhodopsin and a series of mutants. Those simulations
show a strong correlation between the transition dynamics and the pharmacological phenotypes of
the mutants. These results help identify the molecular mechanisms of activation in both wild type
and mutant rhodopsin. While static models can provide insights into the mechanisms of ligand
recognition and predict ligand affinity, a dynamic model of activation could be applicable to study
the pharmacology of other GPCRs and their ligands, offering a key to predictions of basal activity
and ligand efficacy.
Introduction
Rhodopsin is a light sensitive G protein-coupled receptor (GPCR) that is abundantly expressed
in retinal rod cells.1 It consists of a single polypeptide chain, known as opsin, that crosses the
cell membrane with seven α-helical transmembrane domains (TMs). The photoreactive
chromophore 11-cis retinal is covalently bound to the receptor via a Schiff-base linkage to
Lys296. Absorption of light by rhodopsin leads to isomerization of the cis double bond of the
chromophore to the trans form, initiating the cascade of events that ultimately result in receptor
activation and signaling.2 In the course of activation, rhodopsin populates a number of
intermediate states with characteristic spectroscopic signatures. Early photointermediates are
bathorhodopsin (BATHO), a blue-shifted intermediate (BSI), lumi-rhodopsin (LUMI), and
metarhodopsin I (META I),1 where LUMI is the first conformational state in which the retinal
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is found in the all-trans form. Subsequent photointermediates are characterized by the
deprotonation of the Schiff-base linkage. High-affinity interactions with the G protein
transducin (Gt) activate the signaling cascade. Metarhodopsin II (META II) is the first
intermediate capable of initiating signalling.1
Structurally, rhodopsin is the best-characterized GPCR and is considered the prototypical
member of the superfamily. The first X-ray crystallographic structures of rhodopsin reflected
the dark adapted ground state of the bovine receptor, captured in four different crystals, with
resolutions of 2.83, 2.84, 2.655, and 2.2Å6. Molecular dynamics (MD) simulations have been
used extensively to study the dynamic properties of ground state rhodopsin in relation to the
composition of the lipid bilayer7–13. The isomerization of retinal from 11-cis to all-trans was
also simulated to shed light on the structural changes that lead to the LUMI state 14–18.
Furthermore, since until recently direct 3D information was not available for any of the active
states of rhodopsin, different computational approaches were exploited to build models of
META II on the basis of the available experimental information and of proposed activation
mechanisms.16,17,19–23
The first experimental structure of an intermediate of the activation process was published by
Schertler and coworkers, who reported a 2D electron crystallography structure of META I.
24 Solid-state 2H NMR was also recently applied to get insights into the structure of trans-
retinal in META I25,26.
3D crystallographic models of the early photointermediates BATHO (2.6 Å) and LUMI (2.8
Å) were published by Okada et al. 27,28 On the basis of their structures, these authors suggested
that the cis-trans isomerization of retinal affects the interhelical interactions of rhodopsin, that
in turn initiates the process leading to activation.
Determining the structural properties of later intermediates in the rhodopsin photocycle is an
ongoing effort. Recently, a low-resolution (4.15 Å) X-ray structure for a photoactivated
deprotonated intermediate (PDI) of rhodopsin showing absorption maxima consistent with
META II was published by Palczewski et al.29. However, the structure did not confirm the
significant conformational changes or rigid body movement of the TMs expected on the basis
of many published biophysical measurements, including data from electron paramagnetic
resonance spectroscopy (EPR) studies,30–33 UV absorbance spectroscopy,34 zinc cross-
linking of histidines,35 site-specific chemical labeling and fluorescence spectroscopy36. The
constraints of the crystal lattice and the low temperature at which the diffraction data for PDI
were collected may have prevented larger-scale structural rearrangements in this structure.
In this work, we construct a model of the META II structure that incorporates both
crystallographic and biophysical data. We start from the X-ray structure of LUMI28 (pdb code:
2HPY) and apply, in a sequential manner, distance restraints derived from biophysical
measurements. We then compare our META II model with the structures of the ground state
rhodopsin, LUMI and PDI (pdb code: 2I37), and analyze the differences in hydrogen bond
networks. Subsequently, we determine a path leading from LUMI to our model of META II
by using MD simulations, thus generating a dynamic model for rhodopsin activation. We
simulate the transition between the two states for the wild type receptor and various mutants
that have altered activation. The correlation between the ratio of the predicted residence times
of LUMI and META II and the experimental phenotype of the mutations provides
pharmacological support for the model.
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Results and Discussion
Structure of Activated Rhodopsin
A number of biophysical studies offer coarse information on the structural changes associated
with the activation of rhodopsin (Table 1).30,32,33,37,38 The experimental probes are
sensitive to two classes of structural changes. The first group includes the motion associated
with the isomerization of retinal and the perturbations occurring in the binding pocket upon
activation, while the second group includes the global movements of the TM helices.
To build a model of rhodopsin in the META II state, we started from the LUMI x-ray structure
and then drove it toward a putative META II structure by imposing distance restraints obtained
from the two groups of experimental measurements. Restraints sensitive to global motion are
most effective when applied to low resolution models with few degrees of freedom: they could
also be satisfied by local deformations in all-atom models, especially when the number of
available distance restraints is small. In contrast, local changes are more accurately described
by using all-atom models.
Accordingly, the model was constructed in two steps. In the first step, we applied only the
distance restraints derived from the first set of measurements, describing movements in the
binding pocket by using biased MD simulations with an all-atom model. By doing so, we
simulate the activation that starts at the binding pocket due to local rearrangements after retinal
isomerization and propagates to the intracellular part by initiation of global helical movements.
In the ground state of rhodopsin, the protonated retinal forms an ion bridge with E113(3.28,
Ballesteros and Weinstein residue indexing39) in TM3. The isomerization of retinal in LUMI
leads to the formation of META I. In the latter state the counterion of retinal may switch from
E113(3.28) to E181, located in the second extracellular loop (EL2), as indicated by Raman
spectroscopic studies of site-specific mutants of E18140. According to this study, E181(EL2)
was proposed to be protonated in the ground state and to transfer its acidic proton to E113(3.28)
in the course of the activation process However, later results from Fourier-transform infrared
(FTIR) spectroscopy demonstrated that E181(EL2) is deprotonated in the ground state and
proposed that both E113(3.28) and E181(EL2) act as counterions of the protonated retinal in
META I41. Recent results from 2H NMR data and MD simulations of the transformation
leading from ground state rhodopsin to META I, conducted by explicitly simulating the proton
transfer from E181 to E113(3.28) or by considering both residues as deprotonated, supported
the FTIR spectroscopy data15. Taking into account these results, we treated E113 as protonated
and the Schiff base of retinal as deprotonated, as it occurs in the transition from META I to
META II..42 In addition, E134(3.50) of the (E)DRY motif was treated as protonated.43
In this stage of the modeling, the β-ionone ring of retinal moved slightly toward the extracellular
side of the receptor in the direction of TM4 and TM5. Consequently, the sidechains of F212
(5.47), W265(6.48) and F261(6.44) underwent a conformational change and filled the created
cavity. We did not detect a direct interaction between E181 and retinal. These local
perturbations also caused a slight movement of the second extracellular loop (EL2) and the
extracellular end of TM4. The comparison of the root mean square displacements (RMSDs)
of the Ca atoms between LUMI and the model after the first step is shown in Figure 1a.
In the second step, we built an alpha-carbon elastic network model (ENM) of the rhodopsin
structure resulting from the MD simulations. From this model, we computed the atomic
displacements in response to mechanical forces arising from the second set of distance
restraints, describing the global rearrangements of the TMs (see Methods). The smooth
potential of the simplified ENM allows us to extrapolate helix movements from the
experimentally measured pair-wise atomic distances without becoming trapped in local energy
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minima. The RMSD analysis in Figure 1a shows that in the second step the α-helices move
relative to the starting model to satisfy the applied distance restraints, particularly at the
intracellular ends of TM3, TM5, TM6, TM7 and helix 8 We detected significant displacements
for the second and third intracellular loops (ILs) also (Figure 1a). These results are consistent
with the high B-factor values detected in the crystal structure of LUMI for the intracellular
ends of TM3 (135–139), TM5 (221–229) and TM6 (245–249) and for the ILs28. The high
mobility of these regions was also evident from unbiased prolonged MD simulations of the
ground state of rhodopsin 9,16,17,25 and from the analysis of the normal modes of an elastic
network model19.
The displacement of the ENM in response to the applied restraints provided us with a simplified
representation of the global conformational changes that accompany the activation process.
However, the ENM model only includes the alpha-carbon atoms. To obtain an all-atom picture,
we used biased MD to match the Cα atoms of the model obtained in the first step to the
coordinates of the Cα atoms of the ENM. Comparison of our META II model with the PDI
structure and the starting LUMI (Figure 1b) showed that the most significant differences occur
in the loop regions, in helix 8, and at the intracellular ends of TM3, TM4, TM5, TM6 and TM7.
The displacements of the intracellular loops (IL2 and IL3) from LUMI are seen in the PDI
structure, and are more pronounced in our META II model. Figure 1c shows the RMSD of the
Ca atoms from the ground state of rhodopsin (PDB code: 1GZM) for BATHO, LUMI, PDI
and our META II model.
According to a PROCHECK44 analysis, the stereochemical quality of our META II model is
comparable to that of the LUMI X-ray structure28, suggesting that the applied restrains did
not induce large deviations from the typical values of φ, ψ, χ1 and χ2 angles. Ramachandran
and χ1– χ2 plots are shown in Supporting Information (Figures S1 and S2).
In Figure 2, we compare the LUMI structure28 and our final META II model at the large and
local scale. At the large scale, we found significant motions of the transmembrane helices. The
tilting angles between the helix axes of METAII and LUMI, calculated for each transmembrane
helix using the TRAJELIX module45 of the program SIMULAID,46 are small for TM1 and
TM2 (3° and 4.6°, respectively), and somewhat larger for TM3, TM4, TM5, TM6 and TM7
(7.16°, 7.74°, 6.2°, 8.4° and 11.3°, respectively). Comparing our METAII model with the
structure of LUMI, we also detected small counterclockwise rotations around the axes of TM4,
TM5 and TM6 of 5.43°, 10.93°, and 7°, respectively, when viewed from the cytoplasmic side.
These data indicate outward/inward movements of the helices upon activation, coupled to small
rotations of TM4, TM5 and TM6. We also noticed slight kinks in TM5 and TM2 of META II
(Figure 2). The kink in TM5 occurs between H211(5.46) and F212(5.47) and is due to the
absence of the backbone hydrogen bond between H211(5.46) and P215(5.50). The kink in TM2
occurs between G89(2.57) and F88(2.58), and is likely due to the presence of two consecutive
glycines, G89(2.56) and G90(2.57). Locally, the movement of retinal toward the extracellular
part of the receptor causes a rearrangement of the network of aromatic residues. In particular,
we found that the χ1 dihedral angle of W265(6.48) had changed from the g- to the t rotamer.
We will show below that this change in rotamer state is closely coupled to the activation
transition. The conformational flexibility of W265(6.48) was also evident in unbiased MD
simulations of the rhodopsin ground state8 and in computational simulations of the retinal
isomerization reaction16,17,25.
Hydrogen bonds are important contributors to the overall structural stability of a protein. This
is particularly true for membrane proteins where tertiary hydrogen bonding between helices
plays an important role in the low-dielectric membrane environment, somewhat analogous to
hydrophobic interactions in water. To analyze how the network of hydrogen bonds changes in
the different stages of the activation process, we computed the energy of each detectable
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hydrogen bond in the various crystal structures and in our META II model. 2D plots of the
hydrogen bond network colored by energy are given as Supporting Information (Figure S3).
The backbone hydrogen bonds remain stable for the intermediates, while appear to be weaker
for PDI and our META II model. In particular, we observed weakening at the conserved motifs
FX2PX7Y of TM5, FX2CW(Y,F)XP of TM6 and X3NPX2Y of TM7 in proximity of the Pro
kinks; however, the changes are small and could at least in part result from residual strain in
the model caused by application of the restraints.
Significant differences were detected in the hydrogen bond network of the sidechains, which
are critical for membrane proteins. On the basis of different experiments,38,47–51 activation
is thought to be associated with significant changes in the interhelical hydrogen bond network.
The changes suggested by the experiments are reflected in our META II model. In particular,
we noted the disruption of the following pairs of interactions: K296(7.43) and E113(3.28), N55
(1.55) of the conserved motif GX3N and D83(2.50) of the conserved motif N(S)LX3Dx7,8P,
W126(3.41) and E122(3.37), R135(3.50) of the conserved motif D(E)RY and E247(IL3). The
breakage of the latter salt bridge is caused by notable outward movements of the extracellular
ends of TM3 and TM6 and results in a higher accessibility to R135(3.50) of the D(E)RY from
the cytoplasmic side (Figure 2). The possibility of an interaction between this residue and the
G protein has been suggested.52 In summary, our META II model captures the experimentally
demonstrated changes in hydrogen bonding.
We also noted the breakage of the hydrogen bonds between Q64(1.59) and T320 of helix 8,
W126(3.41) and H211(5.46), T243(IL3) and S240(IL3), and N55(1.55) and A299(7.46) in all
photointermediates (Supporting Information, Figure S1). In addition, hydrogen bonds broke
between S187(EL2) and E113(3.28), Y74(2.41) and E150(4.39), as well as W175(EL2) and
S202(5.37) in both PDI and our META II model.
The movement of TM3, TM6, TM7 and helix 8 caused the disruption of the hydrogen bonds
between T320 of helix 8 and H65(IL1), Q225(5.60) and Y136(3.51), N78(2.45) and T160
(4.49), Y191(EL2) and Y268(6.51), Y43(1.38) and F293(7.40), N73(2.40) and Y306(7.53), as
well as M183(EL2) and T289(7.36) in our META II model.
Compensating for the loss of these hydrogen bonds, we found that new hydrogen bonds were
formed to stabilize the changed helical packing in the META II structure: N111(3.26) and P171
(4.61), N111(3.26) and V173(4.63), S186(EL2) and T289(7.36), M288(7.35) and E181(EL2),
289(7.36) and E181(EL2), N302(7.49) and D83(2.50), Q312(helix 8) and N73(2.40), as well
as T94(2.61) and E113(3.28).
The observed structural changes are possible factors in G-protein binding to the activated
receptor. The increased flexibility resulting from weakening and breakage of several hydrogen
bonds may cause the receptor to be more prone to interact with the G protein. At the same time,
the formation of new hydrogen bonds especially in the intracellular loops may modify the
surface to facilitate interactions with the G protein. The conformational perturbation of W265
(6.48), a residue located in the binding pocket and implicated as a molecular switch,24,37 could
be an early event of the relaxation process leading to the activation cascade.
Dynamic Model of Rhodopsin Activation
To provide atomistic insights into the activation mechanism, we generated a dynamic model
of rhodopsin activation. In nature, the conformational transition from LUMI to META II takes
over 6 ms1. Thus, to simulate it with a computer time suitable for a rapid analysis of the
dynamics of rhodopsin activation, we performed biased MD simulations by driving the
transition with mass-weighted RMSD restraints. A similar approach was recently taken to study
the conversion of the cholecystokinin receptor 1 from the inactive to the active form53.
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Although, different molecular compositions of lipid bilayers can substantially affect the
properties of the membrane and consequently the dynamic behaviour of rhodopsin 7,9–11,
17,54,55, here we used the implicit GBSW solvation model56,57 as implemented in
CHARMM58 in order to minimize the computer time necessary to simulate the transition.
Since our simulations are driven with mass-weighted RMSD restraints and are short in time,
we argue that the lack of explicit consideration of the membrane environment does not
substantially affect our results.
The cis-trans isomerization of retinal, which is the first stage of activation, involves crossing
a large energy barrier. To avoid this difficulty, we chose LUMI as a starting point of the
simulations, where the isomerization of the chromophore has already occurred. We follow the
transition by monitoring two characteristic coordinates: the χ1 angle of W265 and the distance
between R135 (3.50) of D(E)RY motif and E247 (i.e., the ionic bridge) as the most significant,
experimentally demonstrated parameters to describe differences between inactive and active
forms of rhodopsin and other GPCRs 24,30,37,49–51.
In bovine rhodopsin the transition between LUMI and META I480, i.e. the conventional META
I which is in equilibrium with META II, appears to be unidirectional1 59. Conversely, LUMI
and META I have been shown to be in equilibrium in chicken rhodopsin.60 Here, in light of
the very small structural differences between LUMI and META I,24 we treated the whole
transition between LUMI and META II as an equilibrium reaction and simulated not only the
forward but also the backward transitions for the wild type receptor and several mutants.
Considering the two forms in equilibrium adds generality to our approach, since this study can
be easily transferred to the analysis of the majority of GPCRs, for which equilibrium is known
to exist. To mimic the conditions of the activation and inactivation processes, the forward
transitions were carried out with protonated E113(3.28)42 and E134(3.49)43, and deprotonated
retinal Schiff base, while the protonation state was the opposite in the backward transitions.
Five trajectories each were generated for forward and backward transitions of wild type
rhodopsin (Figure 3). Initial velocities were chosen from a Maxwell-Boltzmann distribution
with different random seeds. The time evolution of all-atom RMSD, helix tilts and helix kinks
of rhodopsin as well as that of several structural parameters of retinal are shown in the
Supporting Information (Figures S4-7). The kink in TM2 was monitored following the N of
G89(2.57) –C of F88(2.58) – CA of F88(2.58) – N of F88(2.58) dihedral angle. During the
transition, the dihedral angle underwent a change of about 46°. The kink in TM5 was monitored
following the N of H211(5.46) –CA of H211(5.46) – C of H211(5.46) – N of F212(5.46)
dihedral angle. This dihedral angle underwent a change of about 30°. The dihedral angle about
the C6-C7 bond of retinal did not change during the transition from LUMI to META II (Figure
7S, c), indicating that the β-ionone ring of retinal did not change conformation in the course
of the simulation.
The changes of the χ1 angle of W265 located around the retinal binding pocket tend to occur
before the breakage of the salt bridge between R135 (3.50) and E247 in the intracellular part
of rhodopsin in the forward transition. In particular, the χ1 angle of W265 reached the final
value in 66±16 ps, while the distance between R135 (3.50) and E247 reached the final value
in 94±13 ps. The reverse sequence of events was found in the backward transition (i.e., the salt
bridge formed first), with transition times of 116±9 ps for the salt bridge formation and 148±9
ps for the χ1 angle of W265.
A number of rhodopsin mutants showed the ability to either favor or hamper the activation of
the receptor. In the following, we explore possible correlations between the phenotypes of
specific mutations and their effects on the transition times in our dynamic model. We performed
simulations for five mutants that do not affect the folding of the receptor: T94I(2.61),61 A117F
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(3.32),62 G121V(3.36),63 L125Y(3.40),64 and M257Y(6.40)65 (Figure 4). Among them,
T94I(2.61), G121V(3.36), and M257Y(6.40) have been shown to favor activation of the
receptor. They are localized in TM2, TM3 and TM6, respectively. In contrast, A117F(3.32)
and L125Y(3.40) slow the activation transition and are localized in TM3. All substitutions
have hydrophobic character with a larger van der Waals volume than the native residues. In
our simulations, their biological properties seem to be linked to steric effects that selectively
facilitate or hinder the forward or backward transitions.
To assess the effects of the mutations on the rate of conformational changes upon activation,
we perform simulations in which we again drive the transition using mass-weighted RMSD
restraints in CHARMM58. In these biased simulations, we determine the “waiting time” as the
time spent in the initial state before the conformational transition occurs. The absolute waiting
times depend on the restraining procedure. Nevertheless, the relative waiting times can be used
to compare the effects of the different mutations on the rate of the activation transitions.
By monitoring the two reaction coordinates based on five forward and backward trajectories,
we found a clear correlation between predictions of our dynamic model and the phenotypes of
the mutants. For the mutants that favor the activation of the receptor, the forward transitions
are faster and the backward transitions are slower than those of the wild type, resulting in a
shift of the apparent “reaction equilibrium” toward META II, while the opposite happens for
the mutants that impair activation. In Table 2, we show the mean values of waiting times
calculated from five trajectories, together with the standard error of the mean. The forward and
backward transitions for wild type rhodopsin and mutants characterized on the basis of the
distance between R135(3.50) of D(E)RY and E247 are shown on Figure 5. Corresponding
curves for the χ1 angle of W265 are given as Supporting Information (Figure S8).
Following the analysis of the atomic trajectories, we hypothesize a possible mechanism
underlying the phenotype of the mutants. The movement of retinal toward TM4 and TM5 seems
to be facilitated by the T94I(2.61) mutant and obstructed by the A117F(3.32). The change of
the χ1 angle of W265(6.48) is assisted by the G121V(3.36) mutation, but hindered by the L125Y
(3.40) mutation. Lastly, the M257Y(6.40) mutant causes a steric constraint between TM6 and
TM3 that helps the outward movement of TM6.
This dynamic model may be relevant also for other GPCRs for which equilibrium exists
between the inactive and active forms of the receptors. In particular, our analysis provides a
tool for the prediction of mutations that cause enhanced levels of basal activity and a way to
investigate the molecular mechanisms underlying the altered equilibrium between the inactive
and active states of a receptor. These mutants, known as constitutively active, occur naturally
and cause human disease.
Extending this dynamic analysis to GPCRs that bind ligands within their 7-TM bundle could
provide a computational tool for the prediction of the pharmacological properties of ligands.
Just as the approach here was able to distinguish between mutations that accelerate or decelerate
activation, one may distinguish between inverse agonists, antagonist, partial agonists and full
agonists. At least in the case of rhodopsin mutants, our model was able to perform the task,
providing information not accessible by means of static experimental or computational models.
Conclusion
In the first part of the paper, applying experimentally based distance restraints to the structure
of LUMI, we built a model of META II rhodopsin in two steps: first incorporating local
experimental restraints in an all-atom model and then applying global restraints to a coarse
model. We detected significant changes in interhelical hydrogen bonding that may be important
Tikhonova et al. Page 7
J Am Chem Soc. Author manuscript; available in PMC 2009 August 6.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
for the interaction with the G protein, both by enhancing the overall flexibility associated with
“induced-fit” rearrangements and by changing the character of the binding interface.
The structural model we obtained reflects the available experimental information, as compiled
in Table 1. However, it is important to keep in mind that even this extensive set of local and
global distance restraints does not guarantee a unique META II structure. We overcame this
problem by using the coarse network model in conjunction with the more global experimental
restraints. Additional restraints from future distance measurements will permit both a
validation of the existing structural model and further improvements.
In the second part of the paper, we constructed a dynamic model of rhodopsin activation that
describes the path leading from LUMI to our model of META II and vice versa. By providing
atomistic insights into the molecular mechanisms of several mutations that affect activation of
the receptor, the model shows a clear correlation between its dynamic properties and the
pharmacological phenotype of the mutants. In particular, the mutations that facilitate activation
of rhodopsin accelerate the transition to the active state and decelerate the backward transition,
while the opposite happens for the mutants that hamper activation.
We emphasize, however, that the remarkable agreement of the dynamic model with the
phenotype of the respective mutations may at least in part be fortuitous. The effects of amino
acid mutations are often complex and not easily predictable. Here, the number of mutations
considered was significant but by no means large.
While static models can provide insights into the mechanisms of ligand recognition and predict
ligand affinity, dynamic models can be useful in studies of the activation mechanism of GPCRs
and in computational predictions of pharmacology of mutant receptors and novel ligands. The
accuracy and applicability of such dynamic models will be validated in the future, as new
experimental structures become available for the inactive and active states of rhodopsin and
other GPCRs.
Methods
Molecular Dynamics Simulations
MD simulations were performed with CHARMM58 (version c33b2), employing the
CHARMM27 force field66,67. Simulations were carried out in implicit membrane using the
GBSW56,57 (Generalized Born with a simple switching) module of CHARMM. In this
module, the membrane is approximated as a low-dielectric slab which reproduces the Poisson-
Boltzmann electrostatic solvation energy profile across the membrane. Langevin simulations
with a time step of 0.002 ps were performed at a temperature of 300 K. The charges for the
protonated and deprotonated Schiff-base chromophore (retinal and Lys296) were obtained
from a HF/6-31G** calculation in Gaussian.68 The force field parameters for retinal were
taken from the work of Saam and coworkers17.
We applied the HQBM module69 of CHARMM first to force LUMI to satisfy experimentally
derived distance restraints. In a second series of simulations, we forced the all-atom model
toward the Cα scaffold of the ENM model obtained after imposing the global distance restraints.
The lengths of the two simulations were 300 ps and 450 ps, respectively. In HQBM, a progress
variable ρ was defined as the mean squared deviation between the current pair distances rij and
the target distances , over all pairs (ij) in the restraint list:
(1)
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A time-dependent bias potential EHQBM was added to the total energy, which penalizes only
fluctuations that increase ρ, that is:
(2)
where ρ0 is defined as  and the stiffness of the potential is controlled by α, set to
0.6 kcal/mol/Å4.
Mass-weighted RMSD perturbation was performed as implemented in CHARMM58, with a
restraint energy in the form:
(3)
where the RMSD is calculated with respect to the reference structure, ki=800 kcal/mol/Å2 is
a force constant, and Δi is a target value for the relative distance to the reference structure. Five
400-ps simulations each for backward and forward transitions were performed using Maxwell-
Boltzmann initial velocities. In the simulations, the van der Waals radii of the mutated non-
hydrogen sidechain atoms (of M257Y, T94I, L125Y, A117F) were uniformly set to 1.4 Å. The
structures of the rhodopsin mutants were constructed and minimized based on the wild type
structures in the active and inactive states. The waiting time for the completion of the transitions
in these driven simulations was taken as the time until the chosen reaction coordinate moved
within a preset threshold of the final value. For the distance between R135 of D(E)RY and
E247, the final values are 6.80 Å (1.82 Å) for the forward (backward) transition, with thresholds
of 2 Å (1 Å), respectively; for the χ1 angle of W265, the final values are −134.9° (−69°), with
thresholds of 20° (10°). As a measure of the relative stabilities of the initial and final structures,
we calculated the ratio of the waiting times in the forward and backward transitions.
Elastic Network Model and Calculation of Response Displacement
An elastic network model70–72 was constructed based on a Gō-like model73 in which the
springs between alpha-carbon atoms were defined following three rules: (1) sequential carbons
(i,i+1) were connected by “bond” springs with a force constant kb, where kb=378 kcal/
(mol−1 Å−2) is the bond spring constant of the Gō-like model, to capture the stiffness of bonded
and local interactions relative to non-bonded interactions; (2) (i, i+2) and (i,i+3) carbon atoms
(forming “angles” and “dihedrals,” respectively) were connected by springs of spring constant
0.3kb; and (3) Cα pairs forming native contacts according to the Gō-like model were connected
by harmonic springs whose spring constants were obtained from the second derivative at the
minima of the respective pair potentials used in the Gō-like model. The average stiffness of
these “non-bonded” springs was 0.02kb.
As reference conformations, we used the structures obtained after the initial MD simulations
(i.e., with local restraints imposed). For the resulting energy surface E(r), we calculated the
Hessian matrix H such that E(r)≈ rT·H·r/2 where r is the 3N-vector of atomic coordinates. We
then calculated the response of the structure to the experimental distance restraints by applying
external forces on the respective atom pairs in the direction of the pair distance vector. Within
the Hessian approximation, the displacement induced by forces fj acting on atoms j can be
computed as
(4)
where the sum extends over the non-zero eigenvalues of the Hessian matrix H. Δri is the
displacement of atom i, vik and k are the eigenvector and eigenvalue for atom i in the k-th
normal mode, and fj is the external force (3 kcal/mol/Å2) acting on atom j.74 The magnitude
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of the force was chosen empirically to keep the helical structure of TMs. In the first step the
distance restraints between TM1 and TM8, TM1 and TM7, and TM7 and TM7 were applied;
this created space for the movement of TM6 and TM7 when the restraints between TM3 and
TM6 were added in the second step.
Geometric Analysis of Transmembrane Helices
The TRAJELIX module45 of the program SIMULAID46 was used to calculate helix axes,
angles of tilt between METAII and LUMI helix axes, and angles of helix rotation. The residue
ranges of the helices were defined as follow: 34–63 (TM1), 71–99 (TM2), 107–139(TM3),
150–173(TM4), 201–229(TM5), 242–278(TM6), and 284–310(TM7). Changes in geometry
were calculated for the first and last structures along the trajectory from LUMI to METAII.
Calculation of Hydrogen Bonding Energy
Hydrogen atoms were added to the crystal structures and energy minimized using CHARMM.
58 We classified a donor-hydrogen-acceptor interaction as a hydrogen bond if the hydrogen-
acceptor distance was within 3 Å, and the hydrogen-donor-acceptor angle did not exceed 40°.
The energy of the resulting hydrogen bonds was calculated using the DREIDING force field.
75
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Figure 1.
(a) Cα RMSD from the structure of LUMI for the initial all-atom model built based on the first
(local) set of distance restraints (black), the coarse model obtained by applying the second
(global) set of distance restraints (green), and the final all-atom model of META II (red). (b)
Cα RMSD from the structure of LUMI for the PDI structure (black) and the META II model
(red). (c) Cα RMSD from the ground state (PDB code: 1gzm) for BATHO (orange), LUMI
(cyan), PDI (blue) and the META II model (red).
Tikhonova et al. Page 13
J Am Chem Soc. Author manuscript; available in PMC 2009 August 6.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 2.
Superposition of the crystal structure of LUMI (cyan) and the META II model of rhodopsin
(red) shown in cartoon representations (left) and Cα-trace (center). The right panel shows all-
atom representations of the retinal, the covalently bound K296(7.43) and R135(3.50) of the D
(E)RY motif with the partnering E247, and the aromatic residues F212(5.47), F261(6.44), and
W265(6.48).
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Figure 3.
Forward (left) and backward (right) activation transitions of wild type rhodopsin calculated
from five MD trajectories. The transition is monitored by using (a,b) the side-chain dihedral
angle of χ1 of W265(6.48), and (c,d) the distance between R135(3.50) of the D(E)RY motif
and E247.
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Figure 4.
Mutations used to validate the dynamic model of receptor activation. The movement of retinal
toward TM4 and TM5 is facilitated by T94I(2.61) and obstructed by A117F(3.32). The
conformational change of the χ1 angle of W265(6.48) is assisted by G121V(3.36), but is
hindered by L125Y(3.40). M257Y(6.40) causes a steric interaction between TM6 and TM3
that helps the outward movement of TM6. In our dynamic model, the mutations that favor the
activation of the receptor shift the reaction equilibrium toward META II, as deduced from the
rough estimate K=tb/tf based on the waiting times (Table 2). Mutations that impair activation
shift it toward the inactive state.36–40
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Figure 5.
Representative forward (left) and backward (right) transitions for the activation of wild type
rhodopsin (black) and mutants (G121V – red, M257Y – green, T94I - blue, L125Y – yellow
and A117F - brown) chosen from five simulations with different Maxwell-Boltzmann initial
velocities. The transition is monitored by following the distance between R135 of the D(E)RY
motif and E247.
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Table 1
Experimentally measured local and global movements associated with the transition from the ground state to the
activated state of rhodopsin.
First set: Movements in the retinal binding pocket
Measured distances
Ground State (Å) Activated State (Å) Methods
S186 - C14,C15 of retinal 4–5 >6–7 Solid-state NMR38
Y178 - C14,C15 of retinal 10–11 4–5 Solid-state NMR38
W265 - C20 of retinal 3.9 >5.5 Solid-state NMR37
W265 - C19 of retinal 7 ~5 Solid-state NMR37
Cζ3, Cη2 and Cε2 of W265 -
Cα of G121
5.5–6.0 >6 Solid-state NMR37
Second set: Global movements of TMs
Measured distances
Ground State (Å) Activated State (Å) Methods
TM3–TM6
139–248 12–14 23–25 Site-directed
spin-labeling30139–251 12–14 23–25
139–249 15–20 15–20
139–252 15–20 23–25
TM1–TM8
65–316 9–13 9–13+1 Site-directed
spin-labeling32–3365– 319 8–11 8–11+1,
65–312 ~10 ~10+1,2
65–312 10–20 14–18
65–313 ~12 12+1
65–315 10–15 10–15
65–306 8–9 8–9+1
TM1-TM7
65–310 7–14 11–15 (+4)
TM7-TM7
310–316 11–17 14
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